

Table SII. Patient clinical characteristics and early ctDNA variation analysis results

Pat. no.	Age, years	Sex	OMS status	Stage	Mutation	Prior lines of therapy	Cerebral metastasis at baseline	Infusion	ctDNA (copies/ml)	Clinical observation and radiological evaluation at first assessment	Time to progression (days)
1	64	F	1	M1C	NRAS Q61K	No	Absent	C1	296	-	-
								C2	744	Progression	31
								C3	1,576		
6	67	M	0	M1C	NRAS Q61K	Yes (ipilimumab)	Present	C1	8	-	-
								C2	1.28	Response	74
								C3	4		
7	85	M	0	M1C	NRAS Q61K	No	Absent	C1	728	-	-
								C2	-	-	-
								C3	12	Response	145
8	87	F	0	M1A	NRAS Q61K	No	Absent	C1	44.8	-	-
								C2	33.6	Response	221
								C3	-		
9	80	M	1	M1C	NRAS Q61R	Yes (nivolumab)	Absent	C1	48	-	-
								C2	-	-	-
								C3	0	Response	57
11	53	F	0	M1C	NRAS Q61R	No	Present	C1	266	-	-
								C2	8.8	Response	219
								C3	0		
13	52	F	0	M1C	NRAS Q61L	No	Absent	C1	4.8	-	-
								C2	0	Response	538
								C3	0		
14	67	F	0	M1C	NRAS Q61H	Yes (ipilimumab)	Absent	C1	23.2	-	-
								C2	-	-	-
								C3	0	Response	151
15	45	M	1	M1C	BRAF V600E	Yes (dabrafenib then ipilimumab)	Absent	C1	0	-	-
								C2	12.8	Progression	15
								C3	-		
18	59	F	2	M1B	BRAF V600E	Yes (dabrafenib)	Absent	C1	5,032	-	-
								C2	-	-	-
								C3	159.2	Progression	28
19	63	F	2	IIIC	BRAF V600E	Yes (dabrafenib then ipilimumab)	Absent	C1	21.6	-	-
								C2	-	-	-
								C3	62.4	Progression	16
20	59	F	2	M1B	BRAF V600E	Yes (nivolumab)	Absent	C1	11,776	-	-
								C2	-	-	-
								C3	21,448	Progression	21
21	43	F	0	M1C	BRAF V600E	Yes (dabrafenib and trametinib)	Absent	C1	0	-	-
								C2	-	-	-
								C3	220	Progression	54

ctDNA: circulating tumour DNA.